Gillian McGovern, Editor

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

Continuous glucose monitoring (CGM) via interstitial fluid, sweat, and saliva are less invasive than prior methods.

The FDA approves a new dose of Omlyclo, the first interchangeable biosimilar to Xolair, enhancing treatment options for allergic and inflammatory conditions.

The supplemental new drug application (sNDA) was assigned a PDUFA target action date of July 26, 2026.

The blood test helps patients avoid unnecessary and invasive biopsies.

Infants hospitalized with respiratory syncytial virus (RSV) bronchiolitis who were born to parents with asthma had a significantly higher risk of later developing asthma, the investigators found.

The National Association of Boards of Pharmacy Leader Discusses the New Uniform Multistate Pharmacy Jurisprudence Examination (UMPJE), designed to standardize pharmacy law assessment while supporting multistate licensure, regulatory compliance, and patient safety.

Research funding disruptions at the National Institutes of Health (NIH) impact clinical trials, threatening treatment options for patients and highlighting the critical role of pharmacists in care continuity.

Thunderstorms significantly increase asthma-related emergency visits, highlighting the need for storm-specific preparedness and management strategies for patients.

With this approval, Itvisma has become the first and only gene replacement therapy available for children 2 years and older, teenagers, and adults with SMA.

The 1-year extension period in trials will be discontinued based on the efficacy results observed in the overall study population, said Novo Nordisk.

The legislation is effective on January 1, 2026.

Data show the overall use of sodium-glucose cotransporter 2 (SGLT2) inhibitors among study participants with chronic kidney disease (CKD) was about 14.8%.

FDA approves an 8-mg aflibercept injection for macular edema following retinal vein occlusion (RVO), offering flexible dosing options for improved patient care.

Particularly, younger women with chronic kidney disease (CKD) experienced the greatest survival disadvantage.

Emergency medicine pharmacists discuss how they used a gamified, PowerPoint-based virtual escape room to improve disaster preparedness training, strengthen critical thinking, and highlight the essential role of pharmacists in emergency management.

The findings from the BATURA clinical trial were presented at the 2025 ACAAI Annual Scientific Meeting.

The biosimilars can be used to treat osteoporosis and cancer-related bone loss in certain populations.

The research further emphasizes the need for more attention on both chronic kidney disease (CKD) and mental health conditions.

The approval is based on results from the phase 3 DeLLphi-304 clinical trial.

Depemokimab shows significant improvements in asthma symptoms and peak expiratory flow, supporting its twice-yearly use for severe asthma management.

With this action, Thrombate III has become the first and only antithrombin concentrate approved for adult and pediatric patients with hereditary antithrombin deficiency (hATd).

The Annual Meeting Highlighted Emerging Research on Hormone Therapy, Brain and Heart Health, Disparities in Menopause Care, and the Expanding Role of Pharmacists

Patients with non–small cell lung cancer (NSCLC) had an objective response rate of about 77%.

Home monitoring enhances pediatric asthma management, boosting patient engagement and awareness while providing valuable medical feedback for better control.

New findings reveal lorundrostat significantly lowers blood pressure and albuminuria in patients with chronic kidney disease, enhancing standard treatment efficacy.

The FDA approves Poherdy, a new biosimilar to Perjeta, enhancing treatment options for HER2+ breast cancer patients with affordability and efficacy.

Although further data will be presented in 2026, lifileucel shows promise as a 1-time treatment for advanced non–small cell lung cancer (NSCLC).

Razumab, a ranibizumab biosimilar, shows comparable efficacy to its innovator counterpart in treating myopic choroidal neovascular membrane (mCNVM), offering a cost-effective solution.

Pharmacists enhance community health by providing accessible care, managing complex medications, and fostering trust in patient relationships.